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Abstract
Zika virus (ZIKV) is a newly-identified infectious cause of congenital disease. Transplacental
transfer of maternal IgG to the fetus plays an important role in preventing many neonatal
infections. However, antibody transfer may also have negative consequences, such as
mediating enhancement of flavivirus infections in early life, or trafficking of virus immune
complexes to the fetal compartment. ZIKV infection produces placental pathology which
could lead to impaired IgG transfer efficiency as occurs in other maternal infections, such as
HIV-1 and malaria. In this study, we asked whether ZIKV infection during pregnancy impairs
transplacental transfer of IgG. We enrolled pregnant women with fever or rash in a prospec-
tive cohort in Vitoria, Brazil during the recent ZIKV epidemic. ZIKV and dengue virus
(DENV)-specific IgG, ZIKV and DENV neutralizing antibodies, and routine vaccine antigen-
specific IgG were measured in maternal samples collected around delivery and 20 paired
cord blood samples. We concluded that 8 of these mothers were infected with ZIKV during
pregnancy and 12 were ZIKV-uninfected. The magnitude of flavivirus-specific IgG, neutraliz-
ing antibody, and vaccine-elicited IgG were highly correlated between maternal plasma and
infant cord blood in both ZIKV-infected and -uninfected mother-infant pairs. Moreover, there
was no difference in the magnitude of plasma flavivirus-specific IgG levels between mothers
and infants regardless of ZIKV infection status. Our data suggests that maternal ZIKV infec-
tion during pregnancy does not impair the efficiency of placental transfer of flavivirus-spe-
cific, functional, and vaccine-elicited IgG. These findings have implications for the neonatal
outomes of maternal ZIKV infection and optimal administration of antibody-based ZIKV vac-
cines and therapeutics.
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Author summary
In 2015, a Zika virus (ZIKV) epidemic emerged in Latin America, where dengue virus
(DENV) already was endemic. The ZIKV epidemic revealed an array of birth defects and
neurodevelopmental abnormalities in newborns associated with maternal infection. ZIKV
may now be co-endemic in Latin America with DENV. Antibodies transferred from
mother to the fetus in pregnancy can protect newborns from infections in early life, before
they are eligible for vaccination. Conversely, flavivirus-specific IgG transfer could mediate
enhancement of DENV infections in early life, or transfer ZIKV immune complexes into
the fetal compartment. As a first step in evaluating these potential outcomes, it is impor-
tant to understand whether ZIKV infection in pregnancy and its associated placental
pathology impacts the magnitude or types of IgG subpopulations that are transferred
across the placenta. To test this, we assessed paired maternal and cord blood collected at
delivery from mothers who presented with rash and/or fever in pregnancy during the
ZIKV epidemic in Vitoria, Brazil. Of these, we classified 8 as ZIKV-infected based on
virus detection and/or neutralization serology, and 12 as ZIKV-uninfected. Comparing
ZIKV-infected and uninfected groups, we detected no difference in transfer efficiency of
IgG targeting ZIKV, DENV, or routine vaccine antigens. These findings indicate that the
magnitude of IgG transferred across the placenta was not deficient at the time of birth in
the setting of maternal ZIKV infection. Sustained transplacental IgG transfer with ZIKV
infection during pregnancy indicates that ZIKV exposure in utero should not impact
maternal antibody mediated protection during early life. However, concern remains over
potential risk of severe primary DENV infection in ZIKV-exposed infants in endemic
regions, or whether ZIKV could access the fetal compartment via antibody-mediated
transport. This passive antibody transfer in pregnancy is an important consideration for
flavivirus vaccine and therapeutic development efforts.
Introduction
The emergence of Zika virus (ZIKV) in the Americas in 2015 revealed that ZIKV could be con-
genitally transmitted and cause fetal neurological damage [1–3]. Neurodevelopmental defects
associated with congenital Zika syndrome (CZS) include microcephaly, arthrogryposis, motor
and cognitive impairment, as well as vision and hearing loss [4]. ZIKV is the first example of a
teratogenic vector-borne disease in humans. Initial estimates during the epidemic detected a
42% rate of fetal or neonatal abnormalities in symptomatic ZIKV-infected pregnant women
[1], whereas subsequent epidemiologic studies with larger populations estimated a 7–14% rate
of neurological defects in infants of pregnant women infected with ZIKV [5,6]. While the
recent global epidemic has largely waned, the lack of preventative options for protection
against ZIKV suggests ZIKV is likely to be a re-emerging and ongoing cause of congenital
infections.
Transplacental transfer of IgG during pregnancy provides passive immunity to the fetus
and is critical to protecting newborns against infections [7]. Maternal immunization during
pregnancy can boost levels of protective IgG transferred to the fetus, providing a valuable tool
for reducing neonatal morbidity. For example, tetanus immunization of pregnant women, or
women of child-bearing age, resulted in a 94% reduction in neonatal tetanus mortality rates
[8]. Moreover, maternal influenza vaccination and the magnitude of maternally derived anti-
bodies are associated with protection of infants from influenza illness [9–11]. These benefits
have led to the recommendation of providing diphtheria, tetanus, pertussis combined vaccines
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and influenza vaccines routinely during pregnancy [12,13]. Therefore, transplacental transfer
of IgG is an important feature of maternal vaccination and natural immunity that may be lev-
eraged for protection against neonatal pathogens.
Humoral immunity is thought to play an important role in protection against flavivirus
infections [14–16]. ZIKV neutralizing antibodies likely provide durable protection against re-
infection, therefore eliciting robust antibody responses is a key goal of ZIKV vaccine develop-
ment [17]. Given the severe consequences of ZIKV disease in neonates, an ideal ZIKV vaccine
would not only prevent infection in vaccine recipients but also protect fetuses from ZIKV con-
genital transmission. One way to protect fetuses could be transplacental transfer of ZIKV vac-
cine-elicited IgG. However, transplacental transfer of flavivirus-specific IgG also can lead to
enhanced DENV disease during infancy, and may mediate transcytosis of ZIKV immune com-
plexes [18–20]. Due to the key role of antibody transfer for newborn health, it is important to
delineate the quantity and function of IgG transferred from mother to infant during pregnancy
and to determine how transfer is altered by congenital pathogens.
The cross-reactive antibody responses between the antigenically similar DENV and ZIKV
may lead to risks in early life for DENV disease enhancement in infants through transplacental
transfer of flavivirus antibodies [19,21–24]. This risk is known to be mediated by antibodies
generated from a prior DENV infection that can enhance DENV viremia and disease and
ZIKV antibodies may have the potential to similarly enhance DENV infection [25–27]. Timing
of past flavivirus infection also influences this risk as cross-neutralization of DENV and ZIKV
is restricted to early convalescence, and antibody populations become more virus-specific over
time [28,29]. While DENV-specific IgG are efficiently transferred in healthy pregnancies, wan-
ing maternal flavivirus-specific IgG levels throughout the first year of life leads to age-associ-
ated increased risk for severe DENV infection [19,30,31].
A second concern regarding placental IgG transfer is the potential of viral transcytosis from
maternal to fetal compartment with immune complexes and subsequent enhanced fetal infection.
Viruses such as human cytomegalovirus (HCMV) may co-opt this IgG transfer mechanism and
traverse the placenta through the the neonatal Fc receptor (FcRn)[32,33]. Recent work suggests
that ZIKV infection of human placental explants can be enhanced by DENV antibodies [18,34].
However, available epidemiogical data suggest that recent DENV infection provides modest pro-
tection against ZIKV[35,36], highlighting the need to better understand the impact of cross-reac-
tive antibodies in flavivirus disease. Antibody-dependent transfer of ZIKV across the placenta,
antibody-mediated enhancement of DENV disease in infants, and antibody-mediated protection
of fetuses and newborns are all dependent on intact transplacental IgG transfer.
Maternal-fetal IgG transfer occurs at placental villus trees in contact with maternal blood
[33]. In healthy pregnancies, IgG is transferred efficiently such that IgG concentrations in
infant cord blood are often equivalent to or higher than the mother’s levels at delivery [7,37].
Many factors contribute to the efficient transplacental IgG transfer via FcRn, such as IgG sub-
class, antibody avidity, gestational stage, hypergammaglobulinemia [33,38,39], and maternal
conditions or placental pathology.
Therefore, the premise for studying transplacental IgG transfer in the context of ZIKV
infection in pregnancy is twofold. Firstly, maternal HIV-1 infection and placental damage due
to malaria infection are two clinical settings associated with impaired IgG transfer [40–44].
Maternal ZIKV infection also results in placental damage, possibly due to viral infection of
multiple placental cell types and inflammatory immunopathology [45–48]. Interestingly,
maternal infection with DENV, a closely related flavivirus, leads to increased risk of maternal
mortality, pregnancy complications, premature birth, and low infant birth weight, as well as
placental damage [49–53]. Yet, DENV infection in pregnancy does not impair transplacental
IgG transfer in normal birth weight infants [54]. ZIKV infection in pregnancy can result in
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prolonged viremia, suggesting a viral reservoir in an immune privileged site [55–58]. Secondly,
maternal malaria and HIV-1 infection have been established to differentially impact transfer of
IgG subpopulations specific to routine pediatric vaccines [40,59], which may be dependent on
distinct Fc characteristics of each IgG population [60]. This phenomenon impacts antibody
half-life in infant circulation and protection in early life. While prior studies show efficient
transfer of recently boosted flavivirus antibodies after the ZIKV epidemic [61], we further
examined whether pre-existing IgG subpopulations relevant to newborn health are efficiently
transferred following maternal ZIKV infection.
To investigate whether ZIKV infection during pregnancy impairs transplacental transfer of
IgG specific to flaviviruses and common vaccine antigens, we enrolled a prospective cohort of
26 pregnant women from Vitória, Brazil, who presented with fever and rash symptoms consis-
tent with ZIKV infection during the recent Brazilian ZIKV epidemic. Of these women, 20
paired maternal plasma and infant cord blood samples were available from delivery and used
to define the efficiency of transplacental IgG transfer. Evaluating the magnitude and subpopu-
lations of IgG transferred to newborns who are exposed to ZIKV in utero is critical to under-
standing the extent of vaccine protection or risk of severe flavivirus infections in early life, and
the development of antibody-based therapeutics.
Methods
Study population and design
This study enrolled 26 pregnant women living in Southeast Brazil, from which only 20 delivery
samples were collected. All enrollees presented with fever and/or rash during the ZIKV epi-
demic to investigate maternal and infant immunity to ZIKV infection during pregnancy. Two
groups of mother-infant pairs are included in this observational study: one group with mater-
nal ZIKV infection during pregnancy, and the other group without ZIKV infection during
pregnancy. Therefore, mothers with fever or rash during pregnancy but without ZIKV infec-
tion served as a comparator group for those with ZIKV infection and symptomology.
Participants in this study were enrolled from July 2016 to October 2017 in the city of Vitó-
ria, which is the capital of the State of Espı́rito Santo. There are 4 million inhabitants and
50,000 births per year in Espı́rito Santo with the majority living in the metropolitan region of
Vitória [62,63]. This region has had endemic DENV circulation for the past two decades [64]
so it was expected that many participants would have been exposed to DENV previously and
be seropositive for DENV. The first clinically suspected cases of ZIKV infection in Brazil were
described in May 2015, and six months later (November 2015) the first autochthonous ZIKV
case was confirmed in Espı́rito Santo [65–67]. In the months preceding our enrollment, there
was a ZIKV incidence of 3,100 cases per 100,000 inhabitants, and a DENV incidence of 901
cases per 100,000 inhabitants in Espı́rito Santo [64]. In this timeframe, 77 CZS cases were
reported to the State Health Department, including cases of microcephaly, defects of the cen-
tral nervous system suggestive of congenital infection, or stillbirths [64]. Since this region
reflected key features of flavivirus co-endemic settings and had ongoing ZIKV transmission, it
was considered representative of regions with a burden of ZIKV disease and appropriate for
study of maternal and infant ZIKV immunity.
Recruitment
The enrollment field site is based in the city of Vitória at the the Núcleo de Doenças Infecciosas
(NDI), at the Universidade Federal do Espı́rito Santo. During our study, suspected ZIKV infec-
tion was considered a reportable condition to the State Health Department for all patients seen
at public or private clinics within the state. Within a week of a case reported by a physician to
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the State Health Department, a staff member reported notifications of pregnant suspected
ZIKV cases within the State to NDI. Thus the recruitment strategy relied on passive surveil-
lance systems, and no active recruitment was conducted in the community. Upon referral,
staff at the NDI contacted pregnant suspected ZIKV cases within the Vitória metropolitan area
by phone regarding interest in participating in this study. If interested, pregnant suspected
ZIKV cases were invited to the NDI for written informed consent and first recorded visit in
our study at the time of enrollment.
Enrollment and follow-up
At the initial visit for study enrollment, three inclusion criteria were confirmed: 1) pregnant
women with rash or fever; 2) patient was a minimum of 18 years of age; 3) willingness to par-
ticipate in study through provision of written informed consent. No exclusion criteria were
defined. During the enrollment visit, a clinical history and physical evaluation were performed
by a licensed physician, and blood and urine were collected. The following demographic infor-
mation was collected at enrollement: age, municipality, date of birth, last menstrual date, recall
of prior DENV disease, family members or neighbors with symptoms of ZIKV infection, use
of insect repellant, prior vaccination for yellow fever virus, sexual activity in the 10 days before
symptoms of ZIKV infection, symptoms of ZIKV infection in sexual partners, partner’s use of
insect repellent, and use of drugs, tobacco, or alcohol during pregnancy. Any clinical records
and ultrasounds during the pregnancy before symptoms of ZIKV infection also were collected.
All participants were referred for additional prenatal clinical care consultations and ultra-
sounds. Transportation to the NDI research site for every visit, as well as all recommended
consultations with obstetrician-gynecologists and ultrasounds were funded by the study. For
each participant, gestational age at the time of symptoms and delivery was calculated based on
the last menstrual period date and confirmed by ultrasound (performed at 9–22 weeks).
After the enrollment visit, all participants were followed up weekly for up to four weeks,
and monthly visits thereafter until delivery. Though followup of the mothers and infants in
this study is ongoing, the present report only includes samples through delivery. At every visit,
a standardized questionnaire was administered in the form of a semi-structured interview by a
trained research staff member at NDI. Through this questionnaire we collected information
on the presence and duration of symptoms related to ZIKV infection.
At the time of delivery, maternal blood and urine, infant cord blood, and placenta were col-
lected. Newborn head circumference was measured by a nurse prior to hospital discharge, and
reported to study staff. Head circumferences were converted to z score for the corresponding
gestational age using the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project
standards. Microcephaly was defined per WHO and INTERGROWTH-21st guidelines as a z
score lower than -1.88, which is the 3rd percentile of newborns at each gestational age [68,69].
Sample collection
Blood samples were collected into heparin or EDTA tubes, stored at room temperature up to
six hours, and centrifuged at 1300 x G for 10 minutes to obtain plasma. Infant umbilical cord
blood was collected by clamping the cord, cutting it, and draining blood into sterile collection
tubes. Urine samples were collected mid-stream in a sterile screw-top container and stored at
-80˚C. Plasma samples were stored at -80˚C, then shipped to Duke University on dry ice.
Ethics statement
This prospective cohort study was approved by the Institutional Review Board of Hospital Cas-
siano Antonio Moraes, Brazilian National Research Ethics Committee (CEP/CONEP
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Registration number: 52841716.0.0000.5071), and Duke University Medical Center Institu-
tional Review Board (Pro00100218). Women meeting enrollment criteria who provided writ-
ten informed consent were included.
RT-PCR assay for detection of ZIKV
Viral RNA was extracted from 140μL of plasma and urine using QIAmp Viral RNA Mini Kit
(Qiagen). Previously described RT-PCR primers and probes specific for ZIKV were used:
ZIKV1086, ZIKV 1162c, and ZIKV1107-FAM [70]. For this one-step RT-PCR reaction, 5μL of
RNA was combined with 500nM primers, 250nM probe and nucleotides in a total volume of
20μL, including SuperScriptIII RT and Platinum Taq DNA polymerase Mix (Invitrogen). The
negative controls were serum from a 30-year old asymptomatic subject in Vitoria collected in
2016, and PCR grade water (no template control). The positive control was supernatant from
ZIKV-infected Vero cells. Samples and controls were tested in duplicate, and ZIKV positivity
was indicated by detection of amplification at<38 cycles in both duplicate wells on the
Applied Biosystems 7500 Fast platform.
ZIKV IgM antibody capture enzyme-linked immunosorbent assay
(MAC-ELISA)
The CDC MAC-ELISA was adapted and used to detect IgM specific for ZIKV in maternal and
cord blood plasma [71]. Briefly, 96-well high-binding ELISA plates were coated with 20 μg/ml
of mouse anti-human IgM (Sigma #I0759) overnight at 4˚C. Plates were blocked for 30 min-
utes at room temperature with 5% milk in 0.5% TBST, and then samples were added at a 1:40
dilution in quadruplicate for 1 hour at 37˚C. Antigen (ZIKV H/PF/2013 grown in C6/36 cells),
or C6/36 conditioned media as a negative control, was added at a 1:40 dilution overnight at
4˚C. Then, an HRP-conjugated pan-flavivirus antibody (6B6C-1) was added for 1 hour at
37˚C, followed by TMB substrate. Plates were incubated for 20 minutes, upon which 1N
H2SO4 was added to stop the reaction. A positive result required that the absorbance for a par-
ticular plasma was greater than 3-fold higher than the absorbance for that same plasma on C6/
36 conditioned media. Samples run on each plate also include a confirmed ZIKV IgM positive
and negative sample.
Cell culture and virus stocks
Vero-81 cells were grown in Dulbecco’s Modified Eagle Media (Gibco 11965092) supple-
mented with 5% heat-inactivated fetal bovine serum (Cellgro, Cat#35-016-CV) and L-alanyl-
L-glutamine (Thermofisher, GlutaMAX Cat#35050079). Viruses used for the focus reduction
neutralization test were DENV1 (WestPac74), DENV2 (S-16803), DENV3 (CH54389),
DENV4 (TVP-360), obtained from Dr. Aravinda de Silva, University of North Carolina at
Chapel Hill, and ZIKV (H/PF/2013), obtained from the United States Centers for Disease
Control and Prevention (Division of Vector-borne Diseases, Fort Collins, CO). For the detec-
tion of virion binding antibodies, the following viruses from BEI were used: ZIKV (PRVABC59),
DENV1 (Hawaii), DENV2 (New Guinea C), DENV3 (Philippines), and DENV4 (H241). Virus
stocks were grown in Vero-81 cells supplemented with 2% heat-inactivated fetal bovine serum
and 10mM HEPES (Corning, Cat#25-060-CI).
Placental sampling and examination
Placenta samples were available from 11 ZIKV-infected and 8 ZIKV-uninfected subjects out of
26 mothers total in the cohort. Fragments were collected from the whole placenta up to 24
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hours after delivery. Three sets of full thickness samples of placental parenchyma were
obtained in every case and histology performed as previously described [72]. For the histologi-
cal analysis, sections were fixed in 4% formaldehyde phosphate buffered solution, paraffin
embedded, and 5μm sections were stained with hematoxylin and eosin. Histological sections
were examined specifically for villous lesions by a pathologist. Villitis was diagnosed if inflam-
matory exudate was present in the trophoblast or in the villous stroma and was categorized by
Knox & Fox and Redline criteria [73,74]. Placentas were assessed as low-grade villitis if less
than 10 villi were involved per focus, and high-grade if more than 10 villi were involved per
focus [73].
Focus reduction neutralization test
We used previously described methods for FRNT-50 in a 96 well plate [29]. Briefly, serial
5-fold dilutions of heat-inactivated plasma were added to 50–80 focus forming units of either
DENV or ZIKV and incubated for 1 hour at 37˚C, then transferred to a confluent plate of
Vero-81 cells and incubated for 1 hour at 37˚C. Then an overlay of 1% methylcellulose was
added. Cells were fixed with 2% paraformaldehyde and stained with 1 μg/mL of E60 mouse
monoclonal antibody targeting the conserved flavivirus fusion loop [75], then detected with an
anti-mouse IgG horseradish peroxidase conjugate and True Blue substrate (KPL). FRNT-50
values were calculated with the sigmoidal dose-response (variable slope) curve in Prism 7
(GraphPad), constraining values between 0 and 100% relative infection. A valid FRNT-50
curve required an R2 >0.75, hill slope absolute value >0.5, and had to reach at least 50% rela-
tive infection within the range of the plasma dilutions in the assay.
Detection of virion binding IgG
To measure IgG binding responses against whole flavivirus virions, high-binding 96-well
ELISA plates (Greiner) were coated with 30 ng/well of 4G2 antibody (clone D1-4G2-4-15) in
carbonate buffer, pH 9.6 overnight at 4˚C. Plates were blocked in Tris-buffered saline contain-
ing 0.05% Tween-20 and 5% normal goat serum for 1 hour at 37˚C, followed by an incubation
with either ZIKV, DENV1, DENV2, DENV3 or DENV4 for 1 hour at 37˚C. Plasma was tested
at a 1:25 starting dilution in 8 serial 3-fold, 5-fold, or 10-fold dilutions, incubating for 1 hour at
37˚C. Horseradish peroxidase-conjugated goat anti-human IgG antibody (Jackson ImmunoR-
esearch Laboratories, Inc; 109-035-008) was used at a 1: 5,000 dilution, followed by the addi-
tion of SureBlue reserve TMB substrate followed by stop solution (KPL). Optical densities
(OD) were detected at 450 nm (Perkin Elmer, Victor). ED50 values were calculated with the
sigmoidal dose-response (variable slope) curve in Prism 7 (GraphPad), which uses a least
squares fit. An ED50 value was considered valid if the OD at plasma dilution 1:25 was two
(2SD) or three (3SD) standard deviations above the mean OD observed for 11 plasma samples
from healthy U.S. subjects (2SD OD cut-offs: DENV-1 = 0.406, DENV-2 = 0.648, DENV3 =
0.906, and DENV-4 = 0.885; 3SD OD cut-off: ZIKV = 0.596). Software generated ED50 values
from curves with an OD at 1:25 plasma dilution below this cut-off were considered non-bind-
ing and plotted at the limit of detection.
Determination of transplacental transfer of IgG against routine pediatric
vaccines
IgG binding to antigens from pediatric vaccines that are used routinely in Brazil was tested
using a customized binding antibody multiplex assay on the Luminex platform, as previously
described [76]. Pediatric vaccine antigens used for screening included: hepatitis B virus surface
antigen (antigenic combination: adw), rubella virus capsid (AbCam), Bordetella pertussis toxin
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and Corynebacterium diphtheriae toxin (Sigma-Aldrich), Haemophilus influenzae type B oligo-
saccharide-conjugated to human serum albumin (HbO-HA), and tetanus toxoid (Reagent
Proteins). Antibody binding was detected with mouse anti-human IgG-PE (Southern Bio-
Tech) and the fluorescent output was measured on a Bio-Plex 200 system (Bio-Rad Laborato-
ries). Antibody concentrations in μg or International Units per mL were interpolated from
corresponding sigmoidal curves of serially diluted WHO international reference sera (National
Institute of Biological Standards and Control, Potters Bar, UK; NIBSC code numbers: 07/164,
09/222, 06/140, TE-3, 10/262, RUBI-1-94). The efficiency of transplacental IgG transfer was
calculated for each mother-infant pair by dividing the concentration of infant pediatric vac-
cine-specific IgG by the concentration of maternal vaccine-elicited IgG.
Screening for neonatal TORCH pathogens
Data on Toxoplasma, rubella, and syphilis serological status was extracted from the mother’s
prenatal visit clinical records. All tests were performed by State Health Department or clinical
laboratories using commericially available kits approved by the Brazilian Health Regulatory
Agency (ANVISA), as per the manufacturer’s instructions. Chemiluminescent microparticle
immunoassay kits were utilized for detection of Toxoplasma IgM and IgG, as well as rubella
virus IgG. Syphilis serostatus was assessed using a Venereal Disease Research Laboratory test,
which is a nontreponemal test. Congenital HCMV infection was evaluated in our research lab-
oratory using quantitative PCR of infant cord blood. To pellet HCMV from plasma, 200 μL of
infant cord blood was transferred to a high g-force micro-centrifuge tube and spun in an S45A
fixed angle rotor at 30,000 rpm, 4˚C, for 3 hours in a Sorvall Discovery M120 Ultracentrifuge.
Then the supernatant was removed and the pellet re-suspended in 200 μL of 1x PBS. DNA was
extracted using the Roche High Pure Viral Nucleic Acid Kit according to the manufacturer’s
protocol. To quantify and detect HCMV DNA, extracted DNA from each sample was ampli-
fied in six replicates. For this reaction, 5 μL of DNA was added to 15 μL SYBR Select Master
Mix with (ThermoFisher Scientific), 5 μL of water, and 300 nM primers designed to amplify
the immediate-early 1 (IE1) gene of HCMV (Integrated DNA Technologies). IE1 Forward
Primer (20 bp): CAA GCG GCC TCT GAT AAC CA. IE1 Reverse Primer (24 bp): ACT AGG
AGA GCA GAC TCT CAG AGG. For the negative control, PCR grade water was used as a
substitute for extracted DNA in the reaction with in four replicate wells. A 10-fold, 7 series
dilution of plasmid with the amplification region was serially diluted starting at 1x108 copies/
mL to generate a standard curve for quantitation of HCMV DNA in each sample. The lowest
dilution on the standard that could be reliably amplified across replicates was considered as
the threshold for positivity (250 viral DNA copies/mL).
Definition of ZIKV infection
As ZIKV viremia is transient, RT-PCR does not reliably detect ZIKV infection beyond 10–14
days from exposure [77]. Therefore, we combined a RT-PCR diagnostic with serological
approaches based on delivery maternal plasma FRNT-50 titer (FRNT-50) against ZIKV and
DENV (types 1–4). “Primary ZIKV” infection (no prior DENV or ZIKV infection) was defined
as either i) a high ZIKV FRNT-50 (>300) and a low DENV1-4 FRNT-50 (<300), or ii) a low
ZIKV FRNT-50 titer that is still>25 and at least one DENV FRNT-50 >25, suggesting only a
weak transient cross-neutralizing response between ZIKV and DENV. A history of both ZIKV
and DENV (“DENV+ZIKV”) was defined as high ZIKV FRNT-50 (>300), and at least one
DENV FRNT-50>300. DENV immunity only (no ZIKV immunity) was classified as low
ZIKV FRNT-50 (<300), but DENV FRNT-50 >25 (Fig 1). Thus, we defined ZIKV infection as
“primary” or “secondary” ZIKV based on serological evidence of prior DENV exposure,
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whereas the ZIKV-uninfected group may include subjects naïve to both ZIKV and DENV or
those exposed to only DENV.
Since infection with one DENV serotype results in neutralizing activity against that same sero-
type [78], and a subsequent infection with a different serotype results in broad DENV cross-neu-
tralizing activity, we designed criteria to differentiate primary and secondary DENV infections
based on whether the second-highest DENV FRNT-50 was within four-fold of the highest DENV
FRNT-50. To further account for serological cross-reactivity from recently infected subjects in
assessing ZIKV infection status, we confirmed DENV-negative status by RT-PCR where acute
samples were available. Sera with FRNT-50 values below the limit of detection for all five viruses
were classified as ZIKV and DENV naïve. This definition was based on the assumption that a
dominant ZIKV neutralization response at delivery was attributable to the recent symptomatic
illness during pregnancy and not a prior ZIKV infection, given the recency of ZIKV introduction
to the region during the period of enrollment. RT-PCR results from a plasma sample collected
<7 days after symptom onset that were discordant with the serological assessment were repeated.
Statistical analysis and power
Statistical analysis was performed using SAS (version 9.4) and Prism software (GraphPad; ver-
sion 7). Serological responses are presented as a magnitude of flavivirus binding IgG (ED50),
neutralizing (FRNT-50), and vaccine antigen binding IgG (μg/mL or IU/mL). These measures
were assessed for each of the 26 maternal and 20 infant delivery samples, for each antigen
tested (S1 Fig). The percent IgG transferred from mother to infant describes the transplacental
transfer efficiency, and is calculated as the ratio of the magnitude of infant cord blood IgG
binding level (measured as ED50 or μg/ml) to the maternal IgG binding level multiplied by
100. Note that this percent transfer ratio is specific to each antigen tested. Data are presented
as dot plots of percent transfer for each mother infant pair in the ZIKV-infected group as com-
pared to the ZIKV-uninfected group. Scatter plots are used to display the relationship and dis-
tribution of the maternal IgG level as compared to the infant IgG level, by antigen.
Fig 1. Algorithm used to categorize flavivirus exposure history according to ZIKV and DENV focus-reduction
neutralization-50 titers (FRNT-50). Maternal and cord blood plasma were tested by FRNT50 against 5 viruses (ZIKV
and 4 DENV serotypes) and FRNT-50 titers used to infer flavivirus exposure history. All samples were anti-flavivirus IgM
negative, reducing the likelihood of cross-reactivity resulting from recent infections.
https://doi.org/10.1371/journal.pntd.0007648.g001
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With a sample size of 26 mothers and 20 infant samples, our study is powered to reject the
null hypothesis (no correlation between maternal and infant antibody responses), at an alpha
of 0.05 with a power of 0.89 for neutralizing titer correlations, and 0.99 for correlations of IgG
binding to flaviviruses or vaccine antigens. Therefore, this study is adequately powered to
detect associations between maternal and infant antibody measures. For Wilcoxon Rank tests
comparing IgG transfer efficiency between ZIKV-infected and uninfected mothers, this study
is powered to assess significant differences between ZIKV-infected and uninfected groups in
flavivirus IgG binding at an alpha of 0.05 (power = 0.93), but not for vaccine antigen IgG
(power = 0.15) and neutralizing IgG (power = 0.48). This is due to differences in the extent of
variability in measures by assay type.
Due to the small size of this cohort, a Gaussian distribution could not be inferred and there-
fore non-parametric statistical tests were applied. To compare IgG binding between ZIKV-
infected and -uninfected groups, the Wilcoxon Signed and Exact Wilcoxon Rank Sum tests
were applied. For correction of multiple comparisons, the Bonferroni correction was applied.
Data were not stratified beyond the ZIKV infection status exposure group. The Kendall Tau
test was used to evaluate correlations between maternal and infant responses with the alpha
level of significance set to 0.05.
Results
Cohort characteristics
Pregnant women aged 18 to 39 years were enrolled based on symptoms suggestive of ZIKV
infection, such as rash, arthralgia, and fever (Table 1). Nearly all enrolled participants (24/26)
were from the Vitoria metropolitan area. One subject (B1_0037) exhibited prolonged viremia,
which was detected by RT-PCR up to 42 days post symptoms. Mothers were tested for com-
mon congenital “TORCH” pathogens where samples were available (S1 Table). These data
indicate no recent Toxoplasma infections (no maternal IgM positive sera), high IgG seroposi-
tivity to rubella virus, and no evidence for maternal syphillis infection. Testing of infant cord
blood for HCMV DNA found one case of congential HCMV transmission in the ZIKV-unin-
fected group.
Table 1. Symptomatology of patient cohort at the time of enrollment based on ZIKV detection by RT-PCR.
ZIKV PCR+ (n = 9) ZIKV PCR- (n = 13) ZIKV PCR ND (n = 4) Total (n = 26)
9/26 13/26 4/26 26/26
Proportion of mothers symptomatic in each gestational trimester
First 3/9 3/13 2/4 8/26
Second 4/9 7/13 2/4 13/26
Third 2/9 3/13 0/4 5/26
Proportion with symptoms
Rash 8/9 13/13 3/4 24/26
Arthralgia 5/9 4/13 3/4 12/26
Fever 3/9 5/13 3/4 11/26
Conjunctivitis 4/9 4/13 3/4 11/26
Myalgia 5/9 4/13 1/4 10/26
Headache 4/9 7/13 3/4 14/26
Retro-orbital pain 2/9 4/13 2/4 8/26
Lymphadenopathy 1/9 1/13 0/4 2/26
ZIKV = Zika virus, RT-PCR = reverse-transcription polymerase chain reaction, ND = not done.
https://doi.org/10.1371/journal.pntd.0007648.t001
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Serologic profile of flavivirus neutralization
ZIKV testing by RT-PCR was performed in plasma and urine, collected between 2 and 15 days
post symptom onset in 22 out of 26 women (Table 2). According to plasma neutralization
titers, most women were DENV seropositive, regardless of ZIKV infection status. The remain-
ing four women were referred for enrollment only after the resolution of symptoms, at 36 to
217 days since symptoms, and thus their negative ZIKV RT-PCR result was inconclusive. All
women with acute samples available were negative for DENV by RT-PCR at enrollment, and
one (B1_0035) was positive for CHIKV by RT-PCR (S2 Table).
Because ZIKV viremia typically is detected only in the acute phase of infection (�14 days
after exposure), and the possibility of a false positive RT-PCR ZIKV test, we used serology to
classify maternal ZIKV exposure as well as prior DENV infection history. Since detection of
ZIKV-binding antibodies by ELISA does not distinguish ZIKV exposure from other flavivi-
ruses, and this region has high DENV seroprevalence, we determined the FRNT-50 of all
Table 2. ZIKV and DENV serotype specific humoral immune profile. Serologic classification of maternal flavivirus infection history was determined by focus reduction
neutralization titer 50% (FRNT-50) against ZIKV and DENV in plasma taken at delivery.
Sample ID Classification Days since symptoms FRNT50 ZIKV RT-PCR
ZIKV DENV1 DENV2 DENV3 DENV4
B1_0015 Naïve NA <25 <25 <25 <25 <25 -
B1_0019 Naïve 75 <25 <25 <25 <25 <25 -
B1_0021 Naïve 213 <25 <25 <25 <25 <25 -
B1_0039 Naïve 35 <25 <25 <25 <25 <25 ND
B1_0008 Primary ZIKV 184 3918 126 209 251 106 +
B1_0030 Primary ZIKV 77 1399 <25 <25 <25 <25 +
B1_0001 DENV+ZIKV 193 10858 898 597 1270 491 +
B1_0002 DENV+ZIKV 173 14959 1524 666 5571 502 +
B1_0004 DENV+ZIKV 164 2533 1348 1818 3047 537 +
B1_0005 DENV+ZIKV 217 5213 1379 4218 2270 359 +
B1_0007 DENV+ZIKV 208 5503 1371 2511 822 353 ND
B1_0014 DENV+ZIKV 210 3095 354 1625 930 388 -
B1_0031a DENV+ZIKV 94 1610 2723 2492 10521 1510 +
B1_0027 DENV+ZIKV 91 654 1079 1711 3730 513 -
B1_0037 DENV+ZIKV 117 11764 2141 8019 22873 4029 +
B1_0009b Primary DENV2 240 <25 205 1887 238 240 +
B1_0035 Primary DENV2 114 107 68 1201 106 68 -
B1_0011 Primary DENV3 39 <25 374 640 3172 362 -
B1_0006 Primary DENV3 211 <25 89 308 4735 82 ND
B1_0003 Secondary DENV 217 <25 797 122 304 72 -
B1_0016 Secondary DENV 172 <25 232 3222 2051 74 ND
B1_0023 Secondary DENV 92 <25 4417 1693 380 <25 -
B1_0024 Secondary DENV 146 <25 1395 1362 505 299 ND
B1_0026 Secondary DENV 46 <25 2848 1876 635 292 ND
B1_0033 Secondary DENV 91 220 3123 1996 843 197 -
B1_0034 Secondary DENV 111 <25 193 568 939 76 -
ZIKV RT-PCR performed on plasma collected at enrollment (median 146 days since symptoms).
ND = Not Done
a FRNT-50 based on maternal plasma 3 months after delivery
b Likely false positive ZIKV RT-PCR result
https://doi.org/10.1371/journal.pntd.0007648.t002
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maternal plasma samples collected at delivery, which ranged from 39 to 217 days following
onset of ZIKV symptoms. Although DENV and ZIKV antibodies cross-react in binding assays
(e.g. ELISA), we and others have shown that there is minimal cross-neutralizing activity in
convalescent sera [23,29]. By these definitions, 11 out of 26 women had serological evidence of
ZIKV infection, only 2 of which were DENV naïve, indicating a primary ZIKV infection
(Table 2). Two out of 26 women were naïve for both ZIKV and DENV, and the rest had sero-
logical evidence of DENV infection with no ZIKV infection. Though one mother classified as
ZIKV naïve (Primary DENV) by serology (B1_0009) had a positive RT-PCR result at initial
presentation, subsequent RT-PCR testing of stored plasma was negative, suggesting that the
initial result was a false positive. Of note, two patients (B1_0002 and B1_0037) were ZIKV IgM
positive at delivery.
Infant outcomes
At birth, all infants born to ZIKV negative mothers were assessed to be healthy. Of the 11
infants born to mothers with serological evidence of ZIKV infection, one infant (born to
B1_0001) presented with microcephaly at birth, with a head circumference below 3rd percen-
tile based on WHO International Standards, and neurologic abnormalities such as cortical-
subcortical calcifications, dysgenesis of the corpus callosum, pachygyria, and colpocephaly
upon transfontanellar ultrasound and CT scan [79]. Delivery cord blood sample was not avail-
able for this infant. Neurodevelopmental assessments of the infants from this cohort are
ongoing.
Placental histology
Lymphohistiocytic chronic villitis (inflammatory lesions in the placenta with an infiltrate of
lymphocytes and macrophages) [80], was observed in the placentas of 5 of 11 (45%) ZIKV-
infected mothers (Table 3 and Fig 2). The villitis was focal, involving less than 10 villi per
focus, consistent with mild, low grade chronic villitis [73,74]. One placenta (B1_0004) demon-
strated mild necrosis in the villitis focus and two placentas (B1_0004 and B1_0014) demon-
strated small focal avascular villi with stromal fibrosis, consistent with fetal artery thrombosis
in the absence of any other abnormality. We tested frozen placental samples by qRT-PCR but
did not detect ZIKV RNA. In contrast, no vilitis was observed in any of the 8 ZIKV-uninfected
subjects.
Magnitude and kinetics of IgG binding responses to ZIKV and DENV over
the course of pregnancy
ZIKV infection during pregnancy has been associated with prolonged viremia in humans and
non-human primates [55,81–83], and one patient in our study (B1_0037) exhibited prolonged
viremia, with plasma testing positive for ZIKV RNA up to 42 days post onset of symptoms (Fig
3). We compared ZIKV antibody binding dynamics between patient B1_0037 and two other
ZIKV-infected women from the cohort for whom multiple sequential serum and urine sam-
ples were available for analysis (B1_0014 and B1_0030). B1_0030 only tested positive for ZIKV
in urine by RT-PCR at the first 2 visits (within 18 days of symptoms), and B1_0014 tested
ZIKV-negative by RT-PCR but was classified as ZIKV-infected by serology. Of note, these
cases have different flavivirus exposure histories as B1_0014 had prior exposure to DENV, and
B1_0030 had a primary ZIKV infection. The magnitude of maternal plasma IgG binding to
ZIKV, DENV1, DENV2, and DENV4 was measured by virion capture ELISA and neutraliza-
tion was measured by FRNT-50 in plasma collected at every visit during gestation and delivery
(Fig 3). We found that all three subjects sustained high levels of flavivirus-binding IgG and
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neutralizing antibodies throughout pregnancy, with the peak antibody response detectable one
to three weeks post onset of symptoms.
Transplacental transfer of flavivirus-specific and cross-reactive IgG in
ZIKV-infected and uninfected women
To determine if ZIKV infection during pregnancy disrupts transplacental transfer of flavivi-
rus-specific IgG from mother to infant, we compared the magnitude of flavivirus-specific anti-
body binding responses in maternal plasma at delivery and infant cord blood plasma by virion
capture ELISA in 20 mother-infant pairs with delivery samples available. For those with ZIKV
Table 3. Placental pathology. In 5 of 11 ZIKV-infected cases, focal villitis was observed as defined by less than 10 villi
per focus.
Subject Placental Histology Findings
ZIKV infected
B1_0001 Villitis was not observed
B1_0002 Villitis was not observed
B1_0004 Villitis was observed in two foci, consistent with mild, low grade, chronic villitis of unknown etiology,
occurrence of stromal fibrosis and occurrence of necrosis
B1_0005 Villitis was not observed
B1_0007 Villitis was not observed
B1_0008 Villitis was not observed
B1_0031 Villitis was not observed
B1_0027 Villitis was observed in two foci, consistent with mild, low grade, chronic villitis of unknown etiology
B1_0030 Villitis was observed in one focus, consistent with mild, low grade, chronic villitis of unknown etiology
B1_0014 Villitis was observed in two foci, consistent with mild, low grade, chronic villitis of unknown etiology and
occurrence of stromal fibrosis
B1_0037 Villitis was observed in one focus, consistent with mild, low grade, chronic villitis of unknown etiology
ZIKV uninfected
B1_0003 Villitis was not observed
B1_0009 Villitis was not observed
B1_0033 Villitis was not observed
B1_0026 Villitis was not observed
B1_0023 Villitis was not observed
B1_0016 Villitis was not observed
B1_0034 Villitis was not observed
B1_0015 Villitis was not observed
https://doi.org/10.1371/journal.pntd.0007648.t003
Fig 2. Histology of the placenta from a ZIKV-infected pregnant mother. Placental tissue from subject B1_0004 was
stained with hematoxylin and eosin. Lymphocytes and macrophages are present in the chorionic villi (A-100X, B-
400X). The arrow indicates inflammatory cells within a villus.
https://doi.org/10.1371/journal.pntd.0007648.g002
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infection, IgG binding to ZIKV, DENV1, DENV2, DENV3, and DENV4 virions was not sig-
nificantly different between maternal plasma and paired infant cord blood from delivery (Wil-
coxon Signed Rank Test; Bonferroni adjusted P>0.05 for all viruses tested).
We calculated the efficiency of mother-to-fetus transfer of flavivirus-specific IgG as the
ratio of the magnitude of infant cord blood antibody binding response to the maternal
response, expressed as a transfer efficiency percentage (Fig 4 and S3 Table). For those with
paired maternal and infant samples available, we compared the flavivirus-specific IgG transfer
efficiencies in ZIKV-infected (n = 8) and uninfected (n = 12) women, and found no significant
difference in the transplacental transfer efficiency of flavivirus-specific IgG between the groups
(Exact Wilcoxon Rank Sum Test; Bonferroni adjusted P> 0.05 for all viruses tested), indicat-
ing that ZIKV infection during pregnancy did not disrupt transplacental transfer of flavivirus-
specific IgG.
As expected, in the virion capture ELISA we observed cross-reactive binding to ZIKV with
plasma from 8 women who were DENV seropositive but ZIKV-uninfected. These ZIKV-unin-
fected subjects also demonstrated transfer of ZIKV-binding (cross-reactive, non-neutralizing)
Fig 3. ZIKV binding and neutralizing IgG responses persist throughout pregnancy. A. Maternal plasma collected
serially from three women diagnosed with ZIKV during pregnancy was assessed for IgG binding responses to ZIKV
via virion capture ELISA. The estimated dilution at 50% of maximal binding (ED50) was calculated from serial
dilutions of maternal plasma. Black filled points indicate time points when ZIKV viremia was detected by RT-PCR. B.
ZIKV focus reduction neutralization titer throughout pregnancy.
https://doi.org/10.1371/journal.pntd.0007648.g003
Fig 4. Efficient transplacental transfer of flavivirus-specific IgG. Plasma antibody binding to ZIKV, DENV1,
DENV2, DENV3, and DENV4 was measured by virion capture ELISA using serial dilutions of maternal plasma and
infant cord blood collected at delivery. The dilution at 50% of maximal binding (ED50) was calculated and the infant
ED50 was assessed as a percentage of the maternal ED50 to yield percent transfer. Dotted line indicates 100% transfer
and the solid line indicates the median. No significant differences in percent transfer were found in comparing ZIKV-
infected and uninfected women for the all viruses tested by Exact Wilcoxon Rank Sum Test; Bonferroni adjusted
P> 0.05 for all viruses tested.
https://doi.org/10.1371/journal.pntd.0007648.g004
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IgG from mother to infant (Fig 4 and S3 Table). As expected, we did not detect ZIKV-specific
IgG in 2 ZIKV/DENV naïve subjects or in 2 DENV seropositive patients and therefore percent
IgG transfer could not be calculated for these subjects. Of the 8 DENV seropositive subjects
with ZIKV-reactive IgG transferred to cord blood, 5 were seropositive for multiple DENV
serotypes (B1_0016, B1_0024, B1_0026, B1_0033, and B1_0034), and 2 were seropositive for
only a single DENV serotype (B1_0009 and B1_0011), indicating that ZIKV cross-reactive IgG
can be transferred to the fetus in the case of primary or secondary DENV exposure history.
Moreover, percent IgG transfer was not significantly associated with magnitude of the type-
specific IgG in maternal plasma (S2 Fig).
Additionally, we assessed whether there was efficient transplacental transfer of flavivirus
neutralizing IgG in ZIKV-infected pregnant women. The DENV FRNT-50 of paired maternal
and cord blood plasma also were positively correlated, suggesting that functional maternal IgG
were transferred efficiently to the fetus (Fig 5).
Transplacental transfer of vaccine-elicited IgG in ZIKV-infected and
uninfected women
To assess whether ZIKV infection during pregnancy impacts placental transfer of IgG against
vaccine antigens, we measured the magnitude of IgG binding against a panel of standard vac-
cine antigens from hepatitis B virus, rubella virus, Haemophilus influenzae type B, Corynebac-
terium diphtheriae, Bordetella pertussis, and Clostridium tetani. We found no significant
differences in the magnitude of vaccine-specific IgG in maternal plasma and infant cord blood
from delivery, in both ZIKV-infected and uninfected pregnant women (Wilcoxon Signed
Rank Test, P> 0.05 for all vaccine antigens). Moreover, in ZIKV-infected and uninfected
cases, we observed strong positive correlations in the concentration of vaccine-specific IgG
between maternal plasma and infant cord blood for all vaccine antigens tested, indicating effi-
cient placental transfer of vaccine-specific IgG levels regardless of ZIKV infection status (Fig 6
and S3 Table). Based on the protective vaccine-specific IgG levels established by the WHO,
infants born to mothers who had protective levels of vaccine-specific IgG and ZIKV infection
during pregnancy, received similarly protective IgG levels as infants born to ZIKV-naïve
mothers [84].
Fig 5. Maternal ZIKV infection does not disrupt transplacental transfer of DENV neutralizing IgG. Kendall Tau correlation of focus neutralization
reduction titer-50 (FRNT-50) for maternal plasma and infant cord blood, separated by maternal ZIKV serostatus. Panels indicate correlation of maternal and
infant neutralizing titers by flavivirus: ZIKV (A), DENV1 (B), DENV2 (C), DENV3 (D) and DENV4 (E). All correlations are P<0.05, except DENV1 and
ZIKV in ZIKV-infected mothers where P<0.09 and P<0.45 respectively.
https://doi.org/10.1371/journal.pntd.0007648.g005
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Altogether our study demonstrates that efficient transfer of IgG from mother to fetus is main-
tained in this cohort irrespective of maternal ZIKV infection or placental pathology. Furthermore,
this efficient transplacental IgG transfer includes both vaccine-specific antibodies and flavivirus
antibodies relevant to maternal vaccination strategies and flavivirus disease in newborns.
Discussion
Transplacental transfer of IgG provides passive immunity to fetuses, which is critical to pro-
tecting newborns in their first months of life [7]. However, maternal conditions and infections
during pregnancy may disrupt IgG transfer via mechanisms including placental impairment
and inflammatory responses [85]. Moreover, viral antigenic complexity and natural history of
infection shapes the IgG populations elicited, which have different propensities to be trans-
ferred across the placenta by the FcRn [85,86]. Thus, we investigated the impact of maternal
infection with ZIKV on maternal-fetal IgG transfer in 20 mother-infant pairs from a prospec-
tive cohort in Vitoria, Brazil. We assessed transfer of key IgG populations, including ZIKV
and DENV binding and neutralizing IgG, as well as IgG specific to routine vaccine antigens.
For all flavivirus and vaccine antigens tested, we found that maternal and infant binding
IgG levels were highly correlated in both ZIKV-infected and -uninfected groups. Also, there
were no significant differences in the magnitude of flavivirus-binding IgG levels between
Fig 6. Strong correlation of maternal and infant vaccine-elicited IgG levels in ZIKV-infected mothers indicates efficient transplacental transfer
during maternal ZIKV infection. IgG response to vaccine antigens in infant cord blood plasma and maternal plasma collected at delivery were measured
by a binding antibody multiplex assay. Concentrations of vaccine-elicited IgG responses were calculated from reference sera standards as International
Units (IU)/mL or μg/mL. ZIKV-infected (n = 8) and uninfected (n = 12) subjects are indicated in red and black respectively, and dotted lines denote WHO
established protective IgG levels. Kendall Tau correlations were performed for each ZIKV infection group, with p<0.05 for all.
https://doi.org/10.1371/journal.pntd.0007648.g006
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mothers and infants among mothers with ZIKV infection during pregnancy. Moreover,
DENV neutralization and binding IgG levels were highly correlated between mothers and
infants regardless of maternal ZIKV infection in pregnancy. In the case of DENV1 and ZIKV
neutralizing IgG levels, though the positive correlation between mother and infant neutralizing
titer was weak (r = 0.23 and 0.52 respectively), the outliers of the linear trend were shifted such
that the magnitude of infant IgG neutralization is greater than that of the maternal neutralizing
titer, indicating efficient IgG transfer. This positive association of maternal and infant IgG lev-
els represents active transfer that is not solely dependent on the magnitude of the type-specific
IgG in maternal plasma. Also, the substantially overlapping ranges in antibody levels between
mothers and infants suggests no biologically relevant differences in transplacental transfer of
flavivirus binding and neutralizing IgG, or of vaccine specific IgG after ZIKV infection in preg-
nancy. Cumulatively, these data indicate no evidence of impairment in the transplacental IgG
transfer at the time of birth after maternal ZIKV infection during pregnancy, as compared to
mothers with fever and rash during pregnancy without ZIKV infection.
Our study corroborates recent findings demonstrating efficient transfer of ZIKV, DENV3
and DENV4 neutralizing antibodies in mother-infant pairs from the Northeast of Brazil in
2016 [61]. Specifically, Castanha et al. found that newborns with the outcome of micrcephaly,
some of whom were exposed to ZIKV in utero, had no evidence of impaired transfer of neu-
tralizing antibodies at birth as compared to controls without microcephaly [61]. Our work
complements the finding from that case-control study through a prospective cohort design, in
which we identified women with ZIKV infection during pregnancy and followed up until
delivery to quantify impact on transplacental IgG transfer. This prospective design adds a tem-
porality to the association between ZIKV infection and neutralizing IgG transfer oberserved
earlier [61]. Moreover, our study represents a geographically distinct site in Southeast Brazil,
with lower ZIKV prevalence. Altogether, this work strengthens the body of evidence indicating
no impairment in transplacental IgG transfer with ZIKV infection in pregnancy, with implica-
tions for maternal vaccination strategies and flavivirus disease in newborns.
As different viral antigen-specific IgG subpopulations may be differentially impaired in pla-
cental transfer due to maternal infections and conditions during pregnancy [87], we tested
IgG transfer of non-flavivirus antibodies that are specific to diverse vaccine antigens. IgG elic-
ited by routine pediatric and boosted maternal vaccines were also transferred efficiently
despite maternal ZIKV infection. In cases where the mother had a protective level of IgG
against vaccine-preventable infections, the infant received a similarly protective level.
Our study further aimed to complement existing evidence of placental pathology caused by
ZIKV infection, and determine whether this could have a role in the transplacental transfer of
humoral immunity. Previous observations of impaired transplacental IgG transfer in the set-
ting of maternal HIV and malaria infection generally have been noted in conjunction with
identifiable placental pathology [40,85]. Although we were unable to detect ZIKV RNA in pla-
centas from our study, another study identified ZIKV RNA in 54% of placentas from 44
ZIKV-infected women [48]. We found that 5 of 11 ZIKV-infected women in our cohort had
chronic placental villitis, higher than the 5–15% expected for term placentas [88]. Notably, this
pathology is similar to that described in placental infection with HCMV, rubella virus, or
Toxoplasma gondii [80]. In constrast, no vilitis was observed in the 8 placentas assessed from
ZIKV-uninfected mothers, suggesting that vilitis in the ZIKV-infected subjects may have been
specific to maternal ZIKV infection in pregnancy. Furthermore, to assess the impact of ZIKV
infection associated placental pathology on IgG transfer, subgroups of ZIKV-infected subjects
with noted placental pathology would have to be compared to a ZIKV-infected subgroup with-
out placental pathology. However, our limited sample size of 8 ZIKV-infected individuals with
paired infant samples precludes formal comparison
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We found that despite disruption of placental architecture in nearly half of our ZIKV-
infected pregnancies, transplacental transfer of flavivirus-binding and -neutralizing IgG was
sustained following maternal ZIKV infection. This finding is relevant to future studies of vac-
cine-elicited fetal protection against ZIKV, as animal studies demonstrate envelope binding
and neutralizing antibodies as correlates of protection against ZIKV infection [89,90]. Transfer
of flavivirus-neutralizing antibody is relevant because neutralization titers are known to corre-
late with vaccine protection against other flaviviruses, including Japanese encephalitis virus,
yellow fever virus, West Nile virus, and tick-borne encephalitis virus [91–94]. Moreover, in
ZIKV-infected women with serial plasma collection during pregnancy, ZIKV-specific IgG lev-
els were sustained throughout gestation after peak response within 3 weeks of symptoms.
These kinetics suggest that transfer of flavivirus-specific IgG to the fetus should readily occur
throughout the 2nd and 3rd trimesters of pregnancy following maternal ZIKV infection. While
it is possible that ZIKV infection during pregnancy could result in a transient disruption of
transplacental IgG transfer that is restored by the time of birth, our goal was to evaluate levels
of maternal IgG present at delivery as these transferred IgG have the potential to modulate
protection or disease risk in infants [7–10,18,34,95].
There are several implications of the findings in this study. Efficient transfer of ZIKV-neu-
tralizing IgG in ZIKV-infected mothers could be a mode of transferring protective humoral
immunity from mother to infant, despite infection during pregnancy. Notably, transfer of pro-
tective levels of vaccine-specific IgG to boost passive immunity in the newborn is a key objec-
tive of maternal immunization [96] and our findings suggest that ZIKV infection during
pregnancy does not impair this protective mechanism. With candidate maternal ZIKV vac-
cines or therapeutics, this may be one mode of conferring passive immunity to the fetus and,
potentially, reducing the burden of congenital and neonatal ZIKV infection.
Alternatively, transfer of cross-reactive non-neutralizing DENV-elicited antibodies may
pose a risk as antibodies from primary DENV infection can enhance secondary DENV infec-
tion, leading to more severe disease in infants as maternal antibody titers wane [20,25]. We
detected transplacental transfer of ZIKV-binding IgG in DENV-immune mothers without
ZIKV infection. Cross-reactive ZIKV-elicited antibodies may be able to mediate antibody-
dependent enhancement of subsequent DENV infection in early infancy [20,27,97–99]. Addi-
tionally, there is some concern that efficient IgG transfer may facilitate transcytosis of ZIK-
V-IgG complexes into the fetal compartment, a suggested mechanism of fetal infection for
HCMV [18,32]. Thus, transplacental transfer of ZIKV cross-reactive IgG should be considered
in the evaluation of candidate ZIKV vaccines, as sub-neutralizing levels of cross-reactive IgG
may increase the risk of severe flavivirus infections in fetuses or infants.
Limitations of this study include the small sample size of 26 mothers, including 20 mother-
infant pairs with delivery samples available. In assessing statistically significant associations
(alpha = 0.05) via Kendall-Tau correlations between mothers and infants, we had 89% to 99%
power across assays to detect a true direct correlation of maternal and infant IgG levels. There-
fore, our conclusions of intact placental IgG transfer are predominantly based on the high lev-
els of association of maternal and cord blood antibody responses.
As for significant differences in the magnitude of IgG responses between ZIKV-infected
and uninfected mother-infants pairs via the Wilcoxon Signed-Rank Test, this study has a 93%
power to detect differences in flavivirus binding responses between ZIKV-infected and unin-
fected groups (alpha = 0.05). However, the study is underpowered (power < 50%) to detect
significant differences in magnitude of neutralizing or vaccine-specific responses between
ZIKV-infected and -uninfected subjects due to higher levels of variability in these measures.
Consequently, significant differences are only reported and analyzed for the flavivirus-binding
IgG levels, but not for neutralization and vaccine-elicited IgG levels. Though, noting the
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substantially overlapping range of immune responses in the ZIKV-infected group as compared
to the ZIKV-uninfected group is biologically relevant to our understanding of transplacental
IgG transfer in the setting of maternal ZIKV infection and could inform future studies on neo-
natal flavivirus immunity.
Another limitation of our study is the challenge of determining whether subjects were truly
exposed to ZIKV during pregnancy, as symptoms could have resulted from other infections
and/or ZIKV infection could have occurred prior to pregnancy. Since viremia may have sub-
sided by the time of study enrollment, we developed an algorithm to define ZIKV infection
serologically, even in the context of cross-reactive antibodies from prior DENV infection. This
algorithm and ZIKV case definition were based on the rational assumption that ZIKV seropos-
itivity resulted from a recent infection (i.e. during pregnancy) due to the timing of our study
relative to the introduction of ZIKV into Brazil. This assumption will not apply in future stud-
ies, since the high force of infection during the 2015–2017 outbreak and the potential for sub-
sequent endemic transmission mean many women will already be ZIKV seropositive before
pregnancy. Moreover, this study reflects the findings in a symptomatic pregnancy cohort,
whereas the majority of ZIKV infections are asymptomatic[100–102].
In summary, this study demonstrates efficient transplacental transfer of IgG specific to
diverse flavivirus and routine vaccine antigens following ZIKV infection during pregnancy in
a unique prospective mother-infant cohort from the Latin American ZIKV outbreak. Trans-
placental transfer of ZIKV-specific IgG in pregnancy may contribute to protection of the fetus
from congenital Zika syndrome and the infant from ZIKV infection. However, efficiently
transferred IgG might mediate adverse effects in infants including increased risk of severe
DENV in infancy, as well as potentially mediating FcRn-dependent transfer of ZIKV immune
complexes into the fetal compartment. The relationship between efficient maternal IgG trans-
fer and reduced or enhanced congenital infection or disease remains to be further elucidated.
Delineating ZIKV-specific IgG levels and function that favor fetal and neonatal protection will
be key for guiding a strategic timeline for pediatric vaccine boosts, timing of vaccine adminis-
tration during pregnancy, and dosing of antibody therapies targeted for pregnancy. Longitudi-
nal investigations of neonatal immunity, in the context of transplacental transfer of flavivirus
antibodies will be a valuable area of investigation to define serological mediators of risk or pro-
tection for infants. Given the uncertain benefits or risks of efficient transfer of flavivirus IgG,
ZIKV and DENV vaccine strategies will need to carefully consider the timing and type of vac-
cination and boosting in order to maintain protective levels of antibodies in women of repro-
ductive age and infants.
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S1 Fig. Study design flow chart indicating that 26 symptomatic pregnant women were eli-
gible and enrolled into prospective cohort, and only 20 mother-infant pairs were analyzed
due to paired sample availability. The 20 pairs were classified into two groups based on
ZIKV exposure status during pregnancy. Accordingly, 8 mothers were determined to be
infected with ZIKV during pregnancy and 12 were not. Laboratory tests were conducted on all
available mother and infant samples without further stratification.
(TIF)
S2 Fig. Lack of associations between magnitude of maternal flavivirus-specific IgG and
percent IgG transfer. A post-hoc Spearman correlation analysis was conducted to assess
whether higher magnitude of maternal flavivirus IgG due to recency of infection during preg-
nancy could be driving efficient transplacental IgG transfer. No strong positive associations
were noted, suggesting that magnitude of maternal IgG alone does not predict percent transfer
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for each antigen shown (Unadjusted p-values > 0.05 for ZIKV, DENV1, DENV2, DENV4 and
<0.038 for DENV3).
(TIF)
S1 Table. Clinical results of prenatal screening for TORCH infections. These data from
maternal serum samples from pregnany indicate no recent Toxoplasma infections and high
seropositivity to rubella virus as tested by chemiluminescent microparticle immunoassays,
Also, there was no evidence for syphillis, which was assessed by the VDRL test. Infant cord-
blood qPCR testing for CMV indicates one potential case of congential CMV transmission in
the ZIKV-uninfected group. Proportion of mothers or infants with postive test results are
reported as the numerator, whereas the denominator is the number of the total samples tested.
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S2 Table. Timeline of infection for each enrolled mother in this study.
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S3 Table. Transplacental transfer efficiency. Median and range shown for mothers and
infants by each flavivirus binding, vaccine antigen binding or flavivirus neutralizing response
measured. Subjects are grouped by maternal ZIKV infection status to facilitate comparison of
the magnitudes of antibody responses and calculated IgG percent transfer. Infant antibody
response as a portion of maternal response are indicated in the percent transfer column, where
median, range and number of mother-infant pairs per group are shown. Bonferroni adjusted
p-values shown from Wilcoxon Signed Rank Tests to assess significant differences in the
mother to infant percent transfer of antibodies in the ZIKV-infected versus uninfected groups.
No significant differences in the percent transfer of flavivirus binding antibody responses
between mother and infant were observed regardless of ZIKV serostatus. NP indicates that a
p-value is not shown since this study is not powered to detect significant differences between
mothers and infants for those antigens.
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tion with Prolonged Maternal Viremia and Fetal Brain Abnormalities. N Engl J Med. 2016; 374: 2142–
2151. https://doi.org/10.1056/NEJMoa1601824 PMID: 27028667
56. Meaney-Delman D, Oduyebo T, Polen KND, White JL, Bingham AM, Slavinski SA, et al. Prolonged
Detection of Zika Virus RNA in Pregnant Women. Obstet Gynecol. 2016; 128: 724–730. https://doi.
org/10.1097/AOG.0000000000001625 PMID: 27479770
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